Download MendeleyDual 5-HT 2A and 5-HT 2C Receptor Inverse Agonist That Affords In Vivo Antipsychotic Efficacy with Minimal hERG Inhibition for the Treatment of Dementia-Related Psychosis.
Oguma, T., Jino, K., Nakahara, K., Asada, H., Fuchino, K., Nagatani, K., Kouki, K., Okamoto, R., Takai, N., Koda, K., Fujita, S., Sekiguchi, Y., Yasuo, K., Mayumi, K., Abe, A., Imono, M., Horiguchi, N., Iwata, S., Kusakabe, K.I.(2024) J Med Chem 67: 14478-14492
- PubMed: 39137033 Search on PubMed
- DOI: https://doi.org/10.1021/acs.jmedchem.4c01244
- Primary Citation Related Structures:
8ZMF, 8ZMG - PubMed Abstract:
Psychosis is a distressing symptom commonly occurring in people with dementia. To treat Parkinson's disease psychosis, pimavanserin ( 1 ), a 5-HT 2A receptor inverse agonist having minimal 5-HT 2C receptor affinity and no dopamine D 2 receptor affinity, was approved in the United States, but not for dementia-related psychosis due to limited efficacy issues. Herein, we report on the identification of a potent and dual 5-HT 2A and 5-HT 2C receptor inverse agonist 8 having minimal hERG inhibition, after having demonstrated the involvement of both 5-HT 2A and 5-HT 2C receptors to deliver antipsychotic efficacy in an MK-801-induced locomotor model and having conducted 5-HT 2A and 5-HT 2C occupancy studies including a surrogate method. The introduction of a spirocyclopropyl group boosting 5-HT 2C affinity in 1 followed by further optimization to control lipophilicity resulted in balanced dual potency and metabolic stability, and mitigating hERG inhibition led to 8 that showed significant antipsychotic efficacy due to the involvement of both receptors.
- Laboratory for Medicinal Chemistry Research, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan.
Organizational Affiliation:
